IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

CAESAREA, Israel, April 22, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the European Conference on Interventional Oncology 2025 (ECIO), which took place on April 13 – 16, 2025 in Rotterdam, the Netherlands. One of the major areas of focus at ECIO 2025 was breast cancer cryoablation, with ProSense® featuring in seven key events at the conference.

Read more at prnewswire.com